Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23858303 | 0.99 | NR1H4 (0.64) | NR1H4MAOAMAOBNPC1RAB9A | |
| SCHEMBL4414482 | 0.85 | NR1H4 (0.65) | NR1H4MAOAMAOBNPC1RAB9A | |
| SCHEMBL4416033 | 0.85 | NPC1 (0.74) | NR1H4MAOAMAOBNPC1RAB9A | |
| SCHEMBL13135844 | 0.85 | NR1H4 (0.73) | NR1H4MAOAMAOBNPC1RAB9A | |
| SCHEMBL4419275 | 0.85 | NPC1 (0.74) | NR1H4MAOAMAOBNPC1RAB9A | |
| SCHEMBL4419637 | 0.85 | NR1H4 (0.65) | NR1H4MAOAMAOBNPC1RAB9A | |
| SCHEMBL3123292 | 0.85 | NR1H4 (0.72) | NR1H4MAOAMAOBNPC1RAB9A | |
| SCHEMBL30730642 | 0.85 | NR1H4 (0.68) | NR1H4MAOAMAOBNPC1RAB9A | |
| SCHEMBL30730630 | 0.85 | NR1H4 (0.68) | NR1H4MAOAMAOBNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL7551864 | 0.84 | NPC1 (0.72) | NR1H4MAOAMAOBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | claimed |
| EP-1315490-B1 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070117785-A1 | Substituted pyrazoles and methods of treatment with substituted pyrazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-24 | — | — | US | disclosed |
| EP-1309593-B1 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050245576-A1 | Substituted pyrazoles | BUTLER CHRISTOPHER R | 2005-11-03 | — | — | US | disclosed |
| US-6953793-B2 | Substituted pyrazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050101587-A9 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICALS, INC. | 2005-05-12 | — | — | US | disclosed |
| US-6583155-B2 | Administering 2-(1-(3-(5-Acetyl-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-pyrazolo-(4,3 -c)pyridin-1-yl)-2-hydroxy-propyl)-piperidin-4-ylamino)-benzonitrile for inhibiting cathepsins; for treating atopic diseases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1315490-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1309593-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030078419-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-08-22 | — | — | US | disclosed |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-05-09 | — | — | US | disclosed |
| WO-2002020011-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014315-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245576-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | NR1H4 2904/4885MAOA 1285/4885MAOB 841/4885 |
| US-20030078419-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | NR1H4 2904/4885MAOA 1285/4885MAOB 841/4885 |
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | NR1H4 90/4885MAOA 1790/4885MAOB 1651/4885 |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | NR1H4 180/4885MAOA 1126/4885MAOB 1087/4885 |
| US-20050101587-A9 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | NR1H4 180/4885MAOA 1126/4885MAOB 1087/4885 |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | NR1H4 180/4885MAOA 1126/4885MAOB 1087/4885 |
| US-20070117785-A1 | Substituted pyrazoles and methods of treatment with substituted pyrazoles | CTSS, CMA1, CTSZ | NR1H4 1816/4885MAOA 1033/4885MAOB 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.